Completed Research Support

5P30GM110787-Pilot, NIH/NIGMS UK-COBRE

Abisambra, Jose Francisco

04/28/15-04/27/17

PERK inhibition for traumatic brain injury therapeutics

Role: PI

NIRG-14-322441 , Alzheimer's Association

Abisambra, Jose Francisco

02/01/15-01/13/17

The impact of the tau-rpS6 association in the pathogenesis of Alzheimer disease

Role: PI

5UL1TR000117-04 , NIH/NCATS UK-CCTS

Abisambra, Jose Francisco

06/01/15-12/01/16

Innovation and High Impact Award: Manganese-enhanced MRI detection of neuronal dysfunction in pre-symptomatic tauopathy

Role: PI

NIRGD-12-242642, Alzheimer’s Association

Abisambra, Jose Francisco

10/01/12-09/30/14

Mechanism of tau and ER stress for novel Alzheimer’s disease therapeutics

Role: PI

5P30AG028383-00-Pilot, NIH/NIA

Abisambra, Jose Francisco

07/01/13-06/30/14

Head injury-induced tauopathy: role of proteotoxic phospho-tau intermediates

Role: PI

CurePSP-6144107400, CurePSP Foundation

Abisambra, Jose Francisco / Dickey, Chad Anthony

06/01/12-05/31/13

Mechanisms of tau and ER stress for novel PSP and CBD therapeutics

Role: Co-PI

Ongoing Research Support

R01 NS091329-01A1 NIH/NINDS

Abisambra, Jose Francisco

09/30/15-06/30/20

PERK as a central mediator of neurotoxicity in tauopathies

Role: PI

Sub-Contract, American Heart Association

Del Monte, Federica

08/28/17-12/31/19

Myocardial tauopathy: a new pathogenesis and treatment for heart disease

Role: co-I

L32 MD009205-01, NIH/NIMHD

Abisambra, Jose Francisco

07/01/14-06/30/18

Tau as a biomarker for traumatic brain injured patients

Role: PI

GRANT11811993, Department of Defense

Abisambra, Jose Francisco

09/01/15-09/30/18

The impact of PERK on post-traumatic tauopathy in Alzheimer disease

Role: PI

Contract, GlaxoSmithKline

Abisambra, Jose Francisco

04/28/15-04/28/18

PERK inhibition as a therapeutic strategy for Alzheimer disease

Role: PI

Funding & Support

  • Twitter Social Icon